Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 4/20 | 0.38 |
| ▸ | PSEN1 | P49768 | 12/20 | 0.35 |
| ▸ | PSEN2 | P49810 | 12/20 | 0.35 |
| ▸ | APH1B | Q8WW43 | 12/20 | 0.35 |
| ▸ | NCSTN | Q92542 | 12/20 | 0.35 |
| ▸ | APH1A | Q96BI3 | 12/20 | 0.35 |
| ▸ | PSENEN | Q9NZ42 | 12/20 | 0.35 |
| ▸ | APP | P05067 | 4/20 | 0.33 |
| ▸ | NOTCH1 | P46531 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23629607 | 0.93 | RIPK1 (0.44) | RIPK1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL30714806 | 0.93 | RIPK1 (0.44) | RIPK1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL23629603 | 0.92 | RIPK1 (0.44) | RIPK1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL23629609 | 0.84 | RIPK1 (0.40) | RIPK1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL29743515 | 0.78 | APP (0.51) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL23413486 | 0.78 | APP (0.51) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL22494480 | 0.78 | APP (0.51) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL18367188 | 0.76 | RIPK1 (0.61) | RIPK1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL23629615 | 0.76 | RIPK1 (0.34) | RIPK1 | |
| SCHEMBL23939507 | 0.76 | RIPK1 (0.50) | RIPK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12084461-B2 | Bicyclic heteroaryl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2024-09-10 | — | — | US | disclosed |
| EP-3846903-B1 | BICYCLIC HETEROARYL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2023-10-25 | — | — | EP | disclosed |
| EP-3846903-B1 | BICYCLIC HETEROARYL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2023-10-25 | — | — | EP | disclosed |
| US-20210323980-A1 | BICYCLIC HETEROARYL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2021-10-21 | — | — | US | disclosed |
| US-20210323980-A1 | BICYCLIC HETEROARYL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2021-10-21 | — | — | US | disclosed |
| EP-3846903-A1 | BICYCLIC HETEROARYL DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2021-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12084461-B2 | Bicyclic heteroaryl derivatives | AR, CYP1B1, CYP1A1 | RIPK1 4237/4885PSEN1 2562/4885PSEN2 2218/4885 |
| US-20210323980-A1 | BICYCLIC HETEROARYL DERIVATIVES | AR, CYP1B1, CYP1A1 | RIPK1 4237/4885PSEN1 2562/4885PSEN2 2218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.